Rethinking ovarian cancer III: the past decade and future directions

Frances R. Balkwill; Céline M. Laumont; Nikki Burdett; Olivia Le Saux; Dale W. Garsed; Whitney R. Grither; Anke M. Nijhuis; Maria S. Recouvreux; Ziqi Kang; Rugang Zhang; Katherine B. Chiappinelli; Jason S. Lee; Denarda Dangaj Laniti; Iain McNeish; Ahmed A. Ahmed; Robert Rottapel; Jose R. Conejo-Garcia; Kunle Odunsi; Paul D.P. Pharoah; Dmitriy Zamarin; Charles A. Ishak; Christina Fotopoulou; Ronald J. Buckanovich; Intidhar Labidi-Galy; James D. Brenton; Ernst Lengyel; David P. Cook; Sophia H.L. George; Stephanie Lheureux; Ronny Drapkin; Kenneth P. Nephew; Sarah Adams; Shailja Pathania; Brad H. Nelson; Anniina Färkkilä; Katherine Fuh; Benjamin G. Neel; David D. Bowtell

doi:10.1038/s41568-026-00916-0

Rethinking ovarian cancer III: the past decade and future directions

Frances R. Balkwill
, Céline M. Laumont
, Nikki Burdett
, Olivia Le Saux
, Dale W. Garsed
, Whitney R. Grither
, Anke M. Nijhuis
, Maria S. Recouvreux
, Ziqi Kang
, Rugang Zhang
, Katherine B. Chiappinelli
, Jason S. Lee
, Denarda Dangaj Laniti
, Iain McNeish
, Ahmed A. Ahmed
, Robert Rottapel
, Jose R. Conejo-Garcia
, Kunle Odunsi
, Paul D.P. Pharoah
, Dmitriy Zamarin

Charles A. Ishak, Christina Fotopoulou, Ronald J. Buckanovich, Intidhar Labidi-Galy, James D. Brenton, Ernst Lengyel, David P. Cook, Sophia H.L. George, Stephanie Lheureux, Ronny Drapkin, Kenneth P. Nephew, Sarah Adams, Shailja Pathania, Brad H. Nelson, Anniina Färkkilä, Katherine Fuh, Benjamin G. Neel, David D. Bowtell

Biology

Queen Mary University of London
Provincial Health Services Authority
Peter Maccallum Cancer Centre
Centre Léon Bérard
Washington University St. Louis
Imperial College London
University of California at Los Angeles
University of Helsinki
University of Texas MD Anderson Cancer Center
George Washington University
University of Queensland
Ludwig Institute for Cancer Research
University of Oxford
Princess Margaret Cancer Center/University Health Network
Duke University
The University of Chicago
Cedars-Sinai Medical Center
Icahn School of Medicine at Mount Sinai
University of Pittsburgh
University of Geneva
Cancer Research UK Cambridge Institute
University of Ottawa
University of Miami
University of Pennsylvania
Indiana University Bloomington
University of New Mexico
University of California at San Francisco
New York University

Research output: Contribution to journal › Article › peer-review

Abstract

Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead.

Original language	English
Journal	Nature Reviews Cancer
DOIs	https://doi.org/10.1038/s41568-026-00916-0
State	Accepted/In press - 2026

ASJC Scopus Subject Areas

Oncology
Cancer Research

Access to Document

10.1038/s41568-026-00916-0

Cite this

Balkwill, F. R., Laumont, C. M., Burdett, N., Le Saux, O., Garsed, D. W., Grither, W. R., Nijhuis, A. M., Recouvreux, M. S., Kang, Z., Zhang, R., Chiappinelli, K. B., Lee, J. S., Laniti, D. D., McNeish, I., Ahmed, A. A., Rottapel, R., Conejo-Garcia, J. R., Odunsi, K., Pharoah, P. D. P., ... Bowtell, D. D. (Accepted/In press). Rethinking ovarian cancer III: the past decade and future directions. Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00916-0

Balkwill, FR, Laumont, CM, Burdett, N, Le Saux, O, Garsed, DW, Grither, WR, Nijhuis, AM, Recouvreux, MS, Kang, Z, Zhang, R, Chiappinelli, KB, Lee, JS, Laniti, DD, McNeish, I, Ahmed, AA, Rottapel, R, Conejo-Garcia, JR, Odunsi, K, Pharoah, PDP, Zamarin, D, Ishak, CA, Fotopoulou, C, Buckanovich, RJ, Labidi-Galy, I, Brenton, JD, Lengyel, E, Cook, DP, George, SHL, Lheureux, S, Drapkin, R, Nephew, KP, Adams, S, Pathania, S, Nelson, BH, Färkkilä, A, Fuh, K, Neel, BG & Bowtell, DD 2026, 'Rethinking ovarian cancer III: the past decade and future directions', Nature Reviews Cancer. https://doi.org/10.1038/s41568-026-00916-0

@article{509d428e3ce44fb5a7f06e53b7c6b74c,

title = "Rethinking ovarian cancer III: the past decade and future directions",

abstract = "Approximately 80\% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50\% of patients will survive more than 5 years, and just 30\% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead.",

author = "Balkwill, \{Frances R.\} and Laumont, \{C{\'e}line M.\} and Nikki Burdett and \{Le Saux\}, Olivia and Garsed, \{Dale W.\} and Grither, \{Whitney R.\} and Nijhuis, \{Anke M.\} and Recouvreux, \{Maria S.\} and Ziqi Kang and Rugang Zhang and Chiappinelli, \{Katherine B.\} and Lee, \{Jason S.\} and Laniti, \{Denarda Dangaj\} and Iain McNeish and Ahmed, \{Ahmed A.\} and Robert Rottapel and Conejo-Garcia, \{Jose R.\} and Kunle Odunsi and Pharoah, \{Paul D.P.\} and Dmitriy Zamarin and Ishak, \{Charles A.\} and Christina Fotopoulou and Buckanovich, \{Ronald J.\} and Intidhar Labidi-Galy and Brenton, \{James D.\} and Ernst Lengyel and Cook, \{David P.\} and George, \{Sophia H.L.\} and Stephanie Lheureux and Ronny Drapkin and Nephew, \{Kenneth P.\} and Sarah Adams and Shailja Pathania and Nelson, \{Brad H.\} and Anniina F{\"a}rkkil{\"a} and Katherine Fuh and Neel, \{Benjamin G.\} and Bowtell, \{David D.\}",

note = "Publisher Copyright: {\textcopyright} Springer Nature Limited 2026.",

year = "2026",

doi = "10.1038/s41568-026-00916-0",

language = "English",

journal = "Nature Reviews Cancer",

issn = "1474-175X",

publisher = "Nature Research",

}

TY - JOUR

T1 - Rethinking ovarian cancer III

T2 - the past decade and future directions

AU - Balkwill, Frances R.

AU - Laumont, Céline M.

AU - Burdett, Nikki

AU - Le Saux, Olivia

AU - Garsed, Dale W.

AU - Grither, Whitney R.

AU - Nijhuis, Anke M.

AU - Recouvreux, Maria S.

AU - Kang, Ziqi

AU - Zhang, Rugang

AU - Chiappinelli, Katherine B.

AU - Lee, Jason S.

AU - Laniti, Denarda Dangaj

AU - McNeish, Iain

AU - Ahmed, Ahmed A.

AU - Rottapel, Robert

AU - Conejo-Garcia, Jose R.

AU - Odunsi, Kunle

AU - Pharoah, Paul D.P.

AU - Zamarin, Dmitriy

AU - Ishak, Charles A.

AU - Fotopoulou, Christina

AU - Buckanovich, Ronald J.

AU - Labidi-Galy, Intidhar

AU - Brenton, James D.

AU - Lengyel, Ernst

AU - Cook, David P.

AU - George, Sophia H.L.

AU - Lheureux, Stephanie

AU - Drapkin, Ronny

AU - Nephew, Kenneth P.

AU - Adams, Sarah

AU - Pathania, Shailja

AU - Nelson, Brad H.

AU - Färkkilä, Anniina

AU - Fuh, Katherine

AU - Neel, Benjamin G.

AU - Bowtell, David D.

PY - 2026

Y1 - 2026

N2 - Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead.

AB - Approximately 80% of deaths from ovarian cancer are due to high-grade serous carcinoma (HGSC), which has the highest proportion of BRCA1 or BRCA2 (BRCA1/BRCA2) mutations of any cancer type and is a highly chromosomally unstable disease. Despite the introduction of targeted therapies benefitting some patients with HGSC as well as surgical advances, only 50% of patients will survive more than 5 years, and just 30% of patients who present with advanced disease without BRCA1/BRCA2 mutations will survive this long. This Expert Recommendation is based on discussions among emerging and leading ovarian cancer researchers at the 15th Helene Harris Memorial Trust International Forum on ovarian cancer hosted by Ovarian Cancer Action in October 2024. The meeting considered advances in HGSC research and treatment made over the last decade, current challenges, emerging technologies in prevention, early detection, and treatment, and research priorities for the years ahead.

UR - https://www.scopus.com/pages/publications/105035707068

UR - https://www.scopus.com/pages/publications/105035707068#tab=citedBy

U2 - 10.1038/s41568-026-00916-0

DO - 10.1038/s41568-026-00916-0

M3 - Article

C2 - 41975230

AN - SCOPUS:105035707068

SN - 1474-175X

JO - Nature Reviews Cancer

JF - Nature Reviews Cancer

ER -

Rethinking ovarian cancer III: the past decade and future directions

Abstract

ASJC Scopus Subject Areas

Access to Document

Other files and links

Fingerprint

Cite this